• KSBB Journal
• /
• v.5 no.3
• /
• pp.195-200
• /
• 1990

The growth behavior of recombinant Escherichia coli cells having plasmid pIF-III-B, which carries human alpha-interferon gene under the control of lpp promoter, lac promoter and lac operator, was studied by using of various E. coli host strains. Expression of the alpha-IFN gene is controllable by using inducer IPTG because the plasmid also contains lacI gene which produces lac regressors. The repressors block the transcription of alpha-IFN gene. There were considerable differences in cell growth according to the host strains used. Cell growth was inhibited not only by plasmid pIF-III-B itself but also by the induction of alph-a-IFN gene expression. Growth inhibition caused by the plasmid itself was more serious than that caused by the induction of alpha-IFN gene expression.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1993.04a
• /
• pp.131-131
• /
• 1993

위암의 화학요법 성적이 만족스럽지 못하므로 기존의 항암제와 alpha-interferon을 병용사용하므로써 상승적 항암효과가 있는가를 연구하였다. R-25 flask에 위암세포주 SNU-1 및 SNU-16을 배양하면서 항암제 5-FU 혹은 cisplatin에 alpha-interferon 2A(제일제당)를 분자량의 비에 따라 병요처리하였다. 96시간 배양후 cytotoxicity를 Mosman의 방법에 따른 MIT방법으로 분석하였으며, 이를 Chou등의 combination index 분석 program을 처리하였다. 위암세포주 SNU-1에 대하여 5-FU와 alpha-IFN은 상승작용을 보였다. 5-FU의 $IC_{50}$/가 14.25$\mu$M 이었고 IFN처리시는 $IC_{50}$/가 0.02$\mu$M이었으며 combination index(CI)는 모든 용량에서 1이하였다. SNU-16에 대하여도 5-FU와 alpha-IFN의 병용사용은 상승적 작용을 나타내었다. (CI<1.0). cisplatin과 alpha-IFN의 병용시에는 CI가 1이상을 나타내어 상승작용을 증명할 수 없었다.

• Proceedings of the KOR-BRONCHOESO Conference
• /
• 1987.05a
• /
• pp.20.1-20
• /
• 1987

후두 유두종은 후두에서 발생하는 가장 흔한 양성종양이나 임상적으로는 이비인후과영역에서 치유하기 어려운 질환중 하나이다. 1817년 Cheesmann이 성대에서 발생한 유두종을 처음 보고한 이래 많은 보고가 있었으나 아직도 결정적인 치료법이 없는 실정이다. 연자는 수술적 제거후 재발을 방지할 목적으로 Interferon을 술후 7일간은 300,000IU을 매일 피하주사하고 이후는 주 3회에 걸쳐 주사하였으며 동시에 5-FU l00mg을 주 5회 국소분무요법으로 3개월간 병합 실시하여 치료후 평균 3개월 이상 관찰 결과 대상환자 10명중 6명에서는 전혀 재발이 없었고 2명은 현저한 감소, 2명은 재발의 양상을 나타내었다.

• Fisheries and Aquatic Sciences
• /
• v.13 no.1
• /
• pp.56-62
• /
• 2010

To determine whether long double-stranded RNA (dsRNA) induces RNA interference and type I interferon (IFN) responses in fish, long dsRNAs encoding enhanced green fluorescent protein (EGFP), GFPuv, and polyinosinic-polycytidylic acid sequences were co-injected with an EGFP expressing plasmid, into rock bream (Oplegnathus fasciatus). We investigated the EGFP mRNA and protein levels, and the transcriptional responses of dsRNA-dependent protein kinase and Mx1 genes. Long dsRNAs were strong inducers of a type I IFN response in rock bream, resulting in nonspecific suppression of exogenous gene expression. Furthermore, sequence-specific knockdown of exogenous gene expression at the mRNA level was detected at an early phase (24 h). These results suggested that long dsRNA may inhibit exogenous gene expression through an early mRNA interference response and a later type I IFN response in fish.

• Toxicological Research
• /
• v.9 no.1
• /
• pp.107-118
• /
• 1993

LBD-007, a newly developed recombinant human interferon alphaA, was at dose levels of 0.3 $\times$$10^6$ , 6 $\times$ $10^6$ and 12 $\times$ $10^6$ IU/kg/day administered subcutaneously to pregnant and subsequent delivered SpragueDawley rats from day 17 of gestation through day 21 of lactation. Effects of test substance on dams and growth, behaviour and mating performance of F1 offspring were examined. 1. No treatmene-related changes in clinical signs, food consumption, body weight, pregnant period and necropsy findings were observed in dams.

• Proceedings of the Korean Society of Toxicology Conference
• /
• 2002.11b
• /
• pp.194-194
• /
• 2002

Interferon has therapeutic potential for a wide range of infectious and proliferous disorders such as chronic hepatitis C. However, it has drawbacks such as relatively short serum half-life and rapid clearance like other therapeutic proteins. The attachment of a polyethylene glycol (PEG) moiety to interferon is considered as one of the most promising solutions for its ability to extend the plasma residence time.(omitted)

• Toxicological Research
• /
• v.9 no.1
• /
• pp.73-82
• /
• 1993

LBD-007, a newly developed recombinant human interferon alphaA, was at dose levels of 0, 3$\times$$10^6$, 6$\times$ $10^6$ and 12$\times$1$10^6$ IU/kg/day administered subcutaneously to Sprague-Dawley male rats from premating to mating period and to females from premating to early gestation period. Effects of test agent on reproductive performance of both sexes and embryonic development were examined. 1. No treatment-relared changes in food consumption, body weight and necropsy findings were observed in parent animals.

• Toxicological Research
• /
• v.9 no.1
• /
• pp.99-105
• /
• 1993

LBD-007, a newly developed recombinant human interferon alphaA, was at dose levels of 0.3 $\times$$10^6$ , 6 $\times$ $10^6$ and 12 $\times$ $10^6$ IU/kg/day administered subcutaneously to pregnant New Zealand White rabbits during the organogenetic period. Cyclophosphamide was used as a positive control. All pregnant females were subjected to the caesarean section on day 28 of pregnancy. Effect of test substance on dams and embryonal development of fetuses were examined. 1. No treatment-related changes in clinical signs, food consuption, body weight and necropsy findings of dams were observed.

• Toxicological Research
• /
• v.9 no.1
• /
• pp.119-123
• /
• 1993

LBD-007, a newly developed recombinant human interferon ${\alpha}$A, was tested for primary eye and skin irritation in male New Zealand White rabbits. In the primary eye irritation test, 0.1ml of a solution of LBD-007 was instilled into the eye. In rinsing group, the eye was washed with water 30 seconds after instillation. No reaction was observed at the cornea, iris and conjunctivae by LBD-007. In the primary skin irritation test, LBD-007 was applied to the back of rabbits for 24 hours. Primary irritation index was "0" in test and control sites of all animals. Thus LBD-007 was evaluated as a non-irritant on the basis of the criteria of Draize et al.,(1994).

• Toxicological Research
• /
• v.9 no.1
• /
• pp.83-98
• /
• 1993

LBD-007, a newly developed recombinant human interferon alpha A, was at dose levels of 0, 3 $\times$ $10^6$, 6 $\times$ $10^6$ and 12 $\times$ $10^6$ IU/kg/day administered subctaneously to pregnant Sprague-Dawley rats during the organogenetic period. Ethylenethiourea was used as a positive control. 2/3 of dams per group were subjected to caesarean section on day 20 of pregnancy and the remaining 10 dams per group were allowed to deliver. Effects of test substance on dams, embryonal development development of F1 fetuses, as well as growth, behaviour and mating performance of F1 offspring were examined. 1. No treatment-related changes in clinical signs, food consumption, body weight and necropsy findings of dams were observed.